Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation

References

• Sung H, Ferlay J, Siegel R, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Thrift AP. The epidemic of oesophageal carcinoma: where are we now? Cancer Epidemiol. 2016 Apr;41:88–95. doi: 10.1016/j.canep.2016.01.013
   PubMed Web of Science ®Google Scholar
• Rustgi AK, El-Serag HB, Ingelfinger JR. Esophageal carcinoma. N Engl J Med. 2014 Dec 25;371(26):2499–2509.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Hashmi A, Garcia J, et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett’s oesophagus: a case–control study. Gut. 2014 Feb;63:(2):220–229.
   PubMed Web of Science ®Google Scholar
• Njei B, TR M, Birk JW. Trends in esophageal cancer survival in United States adults from 1973 to 2009: a SEER database analysis. J Gastro Hepatol. 2016;31(6):1141–1146. doi: 10.1111/jgh.13289
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines v. Esophageal and esophagogastric junction cancers. 2023 Mar 10. Available from: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf
   Google Scholar
• Obermannová R, Alsina M, Cervantes A, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022 Oct;33:(10):992–1004.
   PubMed Web of Science ®Google Scholar
• Kitagawa Y, Ishihara R, Ishikawa H, et al. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus. 2023 Jul;20:(3):343–372.
   PubMedGoogle Scholar
• Iizuka T, Kakegawa T, Ide H, et al. PhaseII evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese esophageal oncology group trial. Jpn J Clin Oncol. 1992;22(3):172–176.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Ando N, Watanabe H, et al. PhaseII evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) trial (JCOG9407). Japanese Journal of Clinical Oncology. 2001;31(9):419–423. doi: 10.1093/jjco/hye090
   PubMed Web of Science ®Google Scholar
• Hiramoto S, Kato K, Shoji H, et al. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma. Int J Clin Oncol. 2018;23(3):466–472. doi: 10.1007/s10147-018-1239-x
   PubMed Web of Science ®Google Scholar
• Kato K, Tahara M, Hironaka S, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol. 2011;67(6):1265–1272. doi: 10.1007/s00280-010-1422-x
   PubMed Web of Science ®Google Scholar
• Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15(6):955–959. doi: 10.1093/annonc/mdh231
   PubMed Web of Science ®Google Scholar
• Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–1517. doi: 10.1016/S1470-2045(19)30626-6
   PubMed Web of Science ®Google Scholar
• Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–4148. doi: 10.1200/JCO.20.01888
   PubMed Web of Science ®Google Scholar
• Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022 Feb 3;386(5):449–462. doi: 10.1056/NEJMoa2111380
   PubMed Web of Science ®Google Scholar
• Sun JM, Shen L, Shah AM, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. The Lancet. 2021;398(10302):759–771. doi: 10.1016/S0140-6736(21)01234-4
   PubMed Web of Science ®Google Scholar
• Shah MA, Kennedy EB, Alarcon-Rozas AE, et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J Clin Oncol. 2023 Mar 1;41(7):1470–1491. doi: 10.1200/JCO.22.02331
   PubMed Web of Science ®Google Scholar
• Ajani JA, D’Amico TA, Bentrem DJ. Esophageal and Esophagogastric Junction Cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023 Apr;21(4):393–422. doi: 10.6004/jnccn.2023.0019
   PubMedGoogle Scholar
• van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–2084. doi: 10.1056/NEJMoa1112088
   PubMed Web of Science ®Google Scholar
• Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008 Mar 1;26(7):1086–1092. doi: 10.1200/JCO.2007.12.9593
   PubMed Web of Science ®Google Scholar
• Kato K, Ito Y, Daiko H, et al. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. 2022 ASCO Gastrointestinal Cancers Symposium Abstract #238 10.1200/JCO.2022.40.4_suppl.238
   Google Scholar
• Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Eng J Med. 2021 Apr;384:(13):1191–1203.
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018 Mar;18(3):153–167. doi: 10.1038/nri.2017.108
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol. 2018 Oct 1;36(28):2836–2844. doi: 10.1200/JCO.2017.76.6212
   PubMed Web of Science ®Google Scholar
• Boussiotis VA, Longo DL. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016 Nov 3;375(18):1767–1778. doi: 10.1056/NEJMra1514296
   PubMed Web of Science ®Google Scholar
• Guo W, Wang P, Li N, et al. Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. Oncotarget. 2017 Dec 27;9(17):13920–13933. doi: 10.18632/oncotarget.23810
   PubMedGoogle Scholar
• Hato SV, Khong A, de Vries IJ, et al. Molecular pathways: the immunogenic effects of platinum- based chemotherapeutics. Clin Cancer Res. 2014;20(11):2831–2837. doi: 10.1158/1078-0432.CCR-13-3141
   PubMed Web of Science ®Google Scholar
• Chen K, Cheng G, Zhang F, et al. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget. 2016;7(21):30772–30780. doi: 10.18632/oncotarget.8956
   PubMedGoogle Scholar
• Kersten K, Salvagno C, de Visser KE, et al. Exploiting the immunomodulatory properties of chemotherapeutic drugs to improve the success of cancer immunotherapy. Front Immunol. 2015;6:516. doi: 10.3389/fimmu.2015.00516
   PubMed Web of Science ®Google Scholar
• Li C, Zhao S, Zheng Y, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur J Cancer. 2021 Feb;144:232–241. doi: 10.1016/j.ejca.2020.11.039
   PubMed Web of Science ®Google Scholar
• Ye ZM, Xu Z, Wang HL, et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first-line treatment for advanced esophageal cancer. Cancer Med. 2023 Mar;12:(5):6182–6189.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Kato K, Daiko H, et al. FRONTiER: a feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma (JCOG1804E)—the short-term results of cohort a and B. J Clin Oncol. 2021;39(3_suppl):202–2. doi: 10.1200/JCO.2021.39.3_suppl.202
   PubMed Web of Science ®Google Scholar
• Xu J, Yan C, Li Z, et al. Efficacy and safety of neoadjuvant chemoimmunotherapy in resectable esophageal squamous cell carcinoma: a meta-analysis. Ann Surg Oncol. 2023 Mar;30:(3):1597–1613.
   PubMed Web of Science ®Google Scholar
• Kim JH, Ahn B, Hong SM, et al. Real-world efficacy data and predictive clinical parameters for treatment outcomes in advanced esophageal squamous cell carcinoma treated with immune checkpoint inhibitors. Cancer Res Treat. 2022;54(2):505–516. doi: 10.4143/crt.2020.1198
   PubMed Web of Science ®Google Scholar
• Zhang P, Hou X, Cai B, et al. Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world. Ann Transl Med. 2022 Jun;10:(12):708.
   PubMed Web of Science ®Google Scholar
• Wang HC, Huang X, Chen J, et al. Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world. World J Gastroenterol. 2023 Nov 7;29(41):5641–5656. doi: 10.3748/wjg.v29.i41.5641
   PubMed Web of Science ®Google Scholar
• Masuda K, Shoji H, Nagashima K, et al. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer. 2019 Oct 21;19(1):974. doi: 10.1186/s12885-019-6150-y
   PubMed Web of Science ®Google Scholar
• Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018 Mar 1;4(3):374–378. doi: 10.1001/jamaoncol.2017.2925
   PubMed Web of Science ®Google Scholar
• Qin W, Yang L, Fan B, et al. Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer. Front Immunol. 2022 Sep 28;13:931429.
   PubMed Web of Science ®Google Scholar
• Cao R, Wu C, Lv Y, et al. Correlation between immune-related adverse events and treatment efficacy of anti-PD1 immunotherapy in patients with esophageal squamous cell carcinoma. Oncol Lett. 2022 Dec 20;25(2):55. doi: 10.3892/ol.2022.13641
   PubMed Web of Science ®Google Scholar
• Tang K, Seo J, Tiu BC, et al. Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy. JAMA Dermatol. 2022 Feb 1;158(2):189–193. doi: 10.1001/jamadermatol.2021.5476
   PubMed Web of Science ®Google Scholar
• Wu HX, Pan YQ, He Y, et al. Clinical benefit of first-line programmed death-1 antibody plus chemotherapy in low programmed cell death ligand 1-expressing esophageal squamous cell carcinoma: a post hoc analysis of JUPITER-06 and meta-Analysis. J Clin Oncol. 2023 Mar 20;41(9):1735–1746. doi: 10.1200/JCO.22.01490
   PubMed Web of Science ®Google Scholar